# RIBOLARIS (NCT05296746)

> Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05296746
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: SOLTI Breast Cancer Research Group
- Conditions: Breast Cancer Stage II
- Interventions: Ribociclib (neoadjuvant); Chemotherapy (adjuvant); Ribociclib (adjuvant)
- Enrollment: 1100
- Primary outcome: Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 15
- YouTube: 1
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=ribolaris-nct05296746

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05296746", "email": "<work email>"}; the inbox owner confirms by the emailed link.